Annals of Surgical Oncology

, Volume 3, Issue 6, pp 558–563

Evaluation of new putative tumor markers for melanoma

Authors

  • Gregory Miliotes
    • Cutaneous Oncology Program, Moffitt Cancer Center and Research InstituteUniversity of South Florida
  • Gary H. Lyman
    • Division of Medical Oncology, Moffitt Cancer Center and Research InstituteUniversity of South Florida
  • C. Wayne Cruse
    • Cutaneous Oncology Program, Moffitt Cancer Center and Research InstituteUniversity of South Florida
  • Chris Puleo
    • Cutaneous Oncology Program, Moffitt Cancer Center and Research InstituteUniversity of South Florida
  • John Albertini
    • Cutaneous Oncology Program, Moffitt Cancer Center and Research InstituteUniversity of South Florida
  • David Rapaport
    • Cutaneous Oncology Program, Moffitt Cancer Center and Research InstituteUniversity of South Florida
  • Frank Glass
    • Cutaneous Oncology Program, Moffitt Cancer Center and Research InstituteUniversity of South Florida
  • Neil Fenske
    • Cutaneous Oncology Program, Moffitt Cancer Center and Research InstituteUniversity of South Florida
  • Tom Soriano
    • Dianon Systems, Inc.
  • Carole Cuny
    • Dianon Systems, Inc.
  • Nancy VanVoorhis
    • Cutaneous Oncology Program, Moffitt Cancer Center and Research InstituteUniversity of South Florida
  • Douglas Reintgen
    • Cutaneous Oncology Program, Moffitt Cancer Center and Research InstituteUniversity of South Florida
Original Articles

DOI: 10.1007/BF02306089

Cite this article as:
Miliotes, G., Lyman, G.H., Wayne Cruse, C. et al. Annals of Surgical Oncology (1996) 3: 558. doi:10.1007/BF02306089

Abstract

Background: The early diagnosis of recurrent melanoma can contribute to better outcome if the disease can be surgically resected or if the metastases are responsive to systemic therapies. Lipid-associated sialic acid (LASA-P) and the S-100 protein (S-100) were evaluated as tumor markers for melanoma with the goal of early detection of recurrence.

Methods: Sixty-seven patients were identified who had levels of S-100 and LASA-P drawn during their clinical course. A multivariate regression analysis was performed to determine the significance of the serum markers in relation to other prognostic factors for melanoma.

Results: After a median follow-up of 30 months, 58 patients had recurrences, and 49 patients died of disease. LASA-P elevation was not associated with the time to recurrence (p=0.2176) or survival (p=0.2507). S-100 positivity was a significant predictor of recurrence (p<0.0001) and survival (p=0.0059). The median time to recurrence for S-100-positive and S-100-negative patients was 7.6 and 33.8 months, respectively. The median survival time was 59.2 months for S-100-negative patients and 29.6 months for patients positive for S-100.

Conclusions: Serum S-100 shows significant correlations to both time to recurrence and survival and could be useful in the clinical detection of malignant melanoma.

Key Words

Metastatic melanomaTumor markerPrognosis

Copyright information

© The Society of Surgical Oncology, Inc. 1996